X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES MERCK LTD VENUS REMEDIES/
MERCK LTD
 
P/E (TTM) x -693.1 34.2 - View Chart
P/BV x 0.2 3.8 5.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   MERCK LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
MERCK LTD
Dec-16
VENUS REMEDIES/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs2181,060 20.6%   
Low Rs82623 13.2%   
Sales per share (Unadj.) Rs365.6632.4 57.8%  
Earnings per share (Unadj.) Rs1.545.7 3.3%  
Cash flow per share (Unadj.) Rs37.962.3 60.9%  
Dividends per share (Unadj.) Rs011.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs382.5388.8 98.4%  
Shares outstanding (eoy) m11.4416.60 68.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.3 30.8%   
Avg P/E ratio x101.018.4 548.6%  
P/CF ratio (eoy) x4.013.5 29.3%  
Price / Book Value ratio x0.42.2 18.1%  
Dividend payout %024.1 0.0%   
Avg Mkt Cap Rs m1,71713,969 12.3%   
No. of employees `0001.01.6 64.4%   
Total wages/salary Rs m3241,487 21.8%   
Avg. sales/employee Rs Th4,100.76,631.9 61.8%   
Avg. wages/employee Rs Th318.0939.2 33.9%   
Avg. net profit/employee Rs Th16.7479.4 3.5%   
INCOME DATA
Net Sales Rs m4,18310,498 39.8%  
Other income Rs m20242 8.3%   
Total revenues Rs m4,20310,741 39.1%   
Gross profit Rs m8121,135 71.5%  
Depreciation Rs m417276 151.3%   
Interest Rs m3800-   
Profit before tax Rs m351,102 3.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18343 5.3%   
Profit after tax Rs m17759 2.2%  
Gross profit margin %19.410.8 179.4%  
Effective tax rate %51.631.1 165.6%   
Net profit margin %0.47.2 5.6%  
BALANCE SHEET DATA
Current assets Rs m2,7716,410 43.2%   
Current liabilities Rs m1,9318,828 21.9%   
Net working cap to sales %20.1-23.0 -87.1%  
Current ratio x1.40.7 197.6%  
Inventory Days Days12558 216.8%  
Debtors Days Days5438 140.0%  
Net fixed assets Rs m5,3281,406 378.9%   
Share capital Rs m114166 68.9%   
"Free" reserves Rs m4,1776,286 66.5%   
Net worth Rs m4,3766,455 67.8%   
Long term debt Rs m1,9110-   
Total assets Rs m8,4288,828 95.5%  
Interest coverage x1.1NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.2 41.7%   
Return on assets %4.78.6 54.8%  
Return on equity %0.411.8 3.3%  
Return on capital %6.617.1 38.6%  
Exports to sales %08.3 0.0%   
Imports to sales %20.521.0 97.5%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs m8582,209 38.9%   
Fx inflow Rs m0959 0.0%   
Fx outflow Rs m8582,612 32.9%   
Net fx Rs m-858-1,653 51.9%   
CASH FLOW
From Operations Rs m4691,070 43.8%  
From Investments Rs m29-750 -3.9%  
From Financial Activity Rs m-464-150 309.4%  
Net Cashflow Rs m35171 20.2%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.2 18.2 1.0%  
FIIs % 0.6 1.0 58.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 29.1 228.2%  
Shareholders   20,121 28,591 70.4%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS